Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:216
标识
DOI:10.1001/jama.2024.10816
摘要

Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance: Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
豆浆发布了新的文献求助10
刚刚
刚刚
寒冰发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
1秒前
conny完成签到,获得积分10
2秒前
Owen的应助被开心的鸡蛋黄采纳,获得10
2秒前
2秒前
康康发布了新的文献求助10
3秒前
xixi发布了新的文献求助10
3秒前
3秒前
3秒前
刘某发布了新的文献求助10
3秒前
YOYO发布了新的文献求助10
3秒前
yao完成签到,获得积分10
3秒前
深情安青的应助被DoD_K采纳,获得10
4秒前
kk发布了新的文献求助10
4秒前
4秒前
英姑的应助被gentleripper采纳,获得10
4秒前
领导范儿的应助被Vicky采纳,获得10
5秒前
5秒前
Owen的应助被QIQIQI采纳,获得10
5秒前
6秒前
云贝发布了新的文献求助10
6秒前
6秒前
慕青的应助被高梓轩采纳,获得10
7秒前
glacier完成签到,获得积分10
7秒前
7秒前
樱岛芳子完成签到 ,获得积分10
8秒前
JamesPei的应助被gentleripper采纳,获得10
8秒前
xing_xing的应助被典雅惜儿采纳,获得20
8秒前
大太阳发布了新的文献求助10
9秒前
9秒前
CipherSage的应助被wztin采纳,获得10
9秒前
所所的应助被GARYJIANG采纳,获得10
9秒前
nn完成签到,获得积分20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aspects of Post-SPE Phonology 2000
Nanocomposite Removal of Pesticides from Wastewater 1000
Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 888
Rosenblum, Global Change Biology 800
Holistic Discourse Analysis, Second Edition by Robert E. Longacre (2012-09-10) 666
Final Report for the 2-D Test of Model 901 Rotor and Wing Airfoils (BSWT 592) 528
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 物理 有机化学 化学工程 内科学 生物化学 复合材料 催化作用 心理学 细胞生物学 无机化学 电极 光电子学 人工智能
热门帖子
关注 科研通微信公众号,转发送积分 7890956
求助须知:如何正确求助?哪些是违规求助? 9402267
关于积分的说明 20850236
捐赠科研通 7494177
什么是DOI,文献DOI怎么找? 3357963
关于科研通互助平台的介绍 2496338
邀请新用户注册赠送积分活动 2386663